Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 2/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6049474 | 0.93 | MAPK8 (0.55) | PTGER4MAPK8HPGDLMNASMN1; SMN2 | |
| SCHEMBL4085497 | 0.91 | PTGER4 (0.60) | PTGER4MAPK8HPGDGAALMNA | |
| SCHEMBL4086021 | 0.86 | MAPK8 (0.59) | PTGER4MAPK8HPGDGAALMNA | |
| SCHEMBL4081701 | 0.84 | MAPK8 (0.64) | PTGER4MAPK8HPGDLMNASMN1; SMN2 | |
| SCHEMBL4087178 | 0.82 | MAPK8 (0.69) | PTGER4MAPK8HPGDLMNASMN1; SMN2 | |
| SCHEMBL7317640 | 0.82 | MAPK8 (0.75) | PTGER4MAPK8HPGDLMNASMN1; SMN2 | |
| SCHEMBL4085475 | 0.81 | MAPK8 (0.62) | PTGER4MAPK8HPGDLMNASMN1; SMN2 | |
| SCHEMBL7168843 | 0.80 | MAPK8 (0.72) | PTGER4MAPK8GAA | |
| SCHEMBL7371983 | 0.80 | MAPK8 (0.69) | PTGER4MAPK8HPGDLMNASMN1; SMN2 | |
| SCHEMBL4455558 | 0.79 | MAPK8 (0.62) | PTGER4MAPK8HPGDLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043343-A1 | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043343-A1 | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor | PDE3A, PDE4B, PDE12 | PTGER4 230/4885MAPK8 3666/4885HPGD 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.